ESMO 2023 Industry Sponsored Satellite Symposium: Clinical Perspectives on the Evolution of Non-small Cell Lung Cancer Treatment with Immuno-oncology and ROS1 Tyrosine Kinase Inhibitors - European Medical Journal

ESMO 2023 Industry Sponsored Satellite Symposium: Clinical Perspectives on the Evolution of Non-small Cell Lung Cancer Treatment with Immuno-oncology and ROS1 Tyrosine Kinase Inhibitors

Oncology

This symposium was developed and funded by the medical department of Bristol Myers Squibb.


At the 2023 European Society for Medical Oncology (ESMO) Annual Congress, held in Madrid, Spain, Jürgen Wolf, University Hospital Cologne, Germany; Tina Cascone, MD Anderson Cancer Center, Houston, Texas, USA; and Jose Luis Campo-Cañaveral de la Cruz, Puerta de Hierro Majadahonda University Hospital, Madrid, Spain, discussed how the latest data in non-small cell lung cancer may impact treatment selection within an increasingly complex landscape, and the role of the multidisciplinary team in optimising treatment outcomes for patients with resectable disease.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>